Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Neratinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 29,730Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial
    Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial

    07 Dec 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221207005734/en

    BUSINESSWIRE
    07 Dec 2022
    Share Share
    Puma Biotechnology Presents Updated Findings from the PII Trial of Neratinib
    Puma Biotechnology Presents Updated Findings from the PII Trial of Neratinib

    27 Oct 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221027005333/en

    BUSINESSWIRE
    27 Oct 2022
    Share Share
    Puma Announces Agreement with Takeda for the Development of Alisertib
    Puma Announces Agreement with Takeda for the Development of Alisertib

    21 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220920005346/en/Puma-Biotechnology-Announces-Exclusive-License-Agreement-with-Takeda-for-the-Development-and-Commercialization-of-Alisertib-an-Investigational-Aurora-Kinase-A-Inhibitor

    BUSINESSWIRE
    21 Sep 2022
    Share Share
    Puma Presents Findings from the PII SUMMIT Basket Trial of Neratinib
    Puma Presents Findings from the PII SUMMIT Basket Trial of Neratinib

    11 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220911005034/en

    BUSINESSWIRE
    11 Sep 2022
    Share Share
    Sandoz B2B Generic Neratinib Maleate Receives Approval in the U.S.
    Sandoz B2B Generic Neratinib Maleate Receives Approval in the U.S.

    05 Jul 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216236

    FDA
    05 Jul 2022
    Share Share
    Puma Bio Presents Results from Biliary Tract Cohort of PII Trial of Neratinib
    Puma Bio Presents Results from Biliary Tract Cohort of PII Trial of Neratinib

    04 Jun 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220604005003/en

    BUSINESSWIRE
    04 Jun 2022
    Share Share